Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients

Nephrology Dialysis Transplantation

Volumn 21, Issue 2, 2006, Pages 431-436

  Messa, Piergiorgio ^a   Nicolini, Maria Angela ^b   Cesana, Bruno ^c   Brezzi, Brigida ^a   Zattera, Tito ^b   Magnasco, Alberto ^b   Moroni, Gabriella ^a   Campise, Mariarosaria ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Anaemia; Chronic renal failure; Erythropoietin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; IRON; PARATHYROID HORMONE; TRANSFERRIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG USE; ERYTHROCYTE; FEMALE; FERRITIN BLOOD LEVEL; FOLIC ACID BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; IRON BLOOD LEVEL; KIDNEY GRAFT; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT TRANSPORT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PURE RED CELL ANEMIA; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SUPPLEMENTATION; TRANSFERRIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RED-CELL APLASIA, PURE; RENAL DIALYSIS;

EID: 31544442954     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi216     Document Type: Article

References (26)

1. Bommer J, Barth HP, Zeier M et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136-143
2. Muirhead N, Churchill DN, Goldstein M et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992; 12: 303-310
3. Lui SF, Wong KC, Li PKT, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in hemodialysis patients. Am J Nephrol 1992; 12: 55-60
4. Canaud BC, Bennhold I, Delons S et al. What is the optimum frequency of administration of r-Hu-EPO for correcting anemia in hemodialysis patients? Dial Transplant 1995; 24: 306-329
5. Virot JS, Janin G, Guillaumie J et al. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? Am J Kidney Dis 1996; 28: 400-408
6. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583
7. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446
8. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B, on behalf of the Swedish Study Group. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin a: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014-2019
9. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL, on behalf of the Study Group. Once weekly compared with three-times weekly subcutaneous epoetin α: Results from a randomized multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002; 40: 119-125
10. Jacobs C, Hörl WH, Macdougall IC et al. European best practice guidelines 9-13. Anaemia management. Nephrol Dial Transplant 2000; 15: S33-S42
11. Casadevall N, Dupuy E, Molho-Sabatir P et al. Brief report: autoantibodies against erythropoietin in a patient with pure red cell aplasia. N Engl J Med 1996; 334: 630-633
12. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
13. Barré P, Reichel H, Suranyi MG, Barth C. Efficacy of once-weekly epoetin alfa. Clin Nephrol 2004; 62: 440-448
14. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
15. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; i: 1175-1178
16. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-78
17. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: 1-47
18. Leikis MJ, Kent AB, Becker GJ, McMahon LP. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Nephrology 2004; 9: 153-160
19. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182-S238
20. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99-113
21. Macdougall IC. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 [Suppl 5]: 66-70
22. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (EPO) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002; 69: 265-274
23. Bommer J, Barth HP, Zeier M et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136-143
24. Alfrey CP, Udden MM, Huntoon CL, Driscoll TB, Pickett MH. Control of the red cell mass in spaceflight. J Appl Physiol 1996; 81: 98-104
25. Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W. Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 1999; 33: 59-62
26. Trial J, Rice L, Alfrey CP. Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: An in vitro model of neocytolysis. J Invest Med 2001; 49: 335-345